RXi Pharmaceuticals Corporation (NASDAQ:RXII) rose to $0.85 per share in the last trading day compared to a prior close of $0.79. The management team hold 14.1 percent of the stock. Cauwenbergh Geert ranks as top insider in RXi Pharmaceuticals Corporation, noted in the Company’s filings with the U.S. Securities and Exchange Commission. The insider’s stake of 172,500 shares is worth $146,625. Bitterman Robert J is ranked No.2 with 44,000 shares as of Jun 02, 2015, which sits at a market value around $37,400. Dorman H. Paul is another big name in this category. This insider owns 37,500 RXII shares, amounting to about $31,875 as of recent trading price which is 19.99% above its 20-day moving average and -47.18% below its 50-day moving average. The equity dropped -49.99% over the trailing 3 months.
RXi Pharmaceuticals Corporation (NASDAQ:RXII) on February 14, 2017 announced the appointment of James D. Griffin, MD, Chairman, Department of Medical Oncology, Dana-Farber Cancer Institute, to its Scientific Advisory Board. Dr. Griffin also serves as Professor, Medicine, Harvard Medical School and Director, Medical Oncology, Brigham and Women’s Hospital.
Dr. Griffin received his medical degree from Harvard Medical School in 1974. After residency training in internal medicine at Johns Hopkins Hospital, he completed a hematology fellowship at Massachusetts General Hospital and a medical oncology fellowship at Dana-Farber. In 1981, he joined the staff of Dana-Farber, where he is chair of the Department of Medical Oncology.
From 1993 to 1998, Dr. Griffin was editor-in-chief of Blood. He is a professor of Medicine at Harvard Medical School and currently sits on the scientific advisory boards of the Lombardi Cancer Center at Georgetown University and the Johns Hopkins Cancer Center and Case Western Cancer Center.
Fate Therapeutics, Inc. (NASDAQ:FATE) shares closed at $5.05, up 0.25 points or 5.21 percent from the previous close price. The up to date insider trading filings show Chief Medical Officer Storgard Chris has picked up 37,593 shares,upping the ownership to 46,683 units. The transaction occurred on Nov 23, 2016, at $2.66 per share worth a total $100,000. There was another major transaction on the insider-trading front. RASTETTER WILLIAM H, Director at FATE bought 375,939 common shares at a per share price of $2.66 to hold 577,632 shares. The stock recently traded at a volume of 0 shares vs. an average volume of 251.00K. The latest closing price is now higher 67.22% for the past quarter. The price is now 53.79% above its 50-day moving average and 92.39% above its 200-day moving average. The percentage change return over the last fifty two weeks remained 177.47%. The price range in the same period had a highest hit of $5.68 while lowest level in that period was $1.47.
Fate Therapeutics, Inc. (NASDAQ:FATE) on March 13, 2017 announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug application for FATE-NK100, the Company’s first-in-class adaptive memory natural killer (NK) cell product candidate. The Company expects a first-in-human clinical trial of FATE-NK100 for advanced acute myeloid leukemia (AML) to open enrollment at the Masonic Cancer Center, University of Minnesota following approval of the Center’s institutional review board.
FATE-NK100 is comprised of adaptive memory NK cells, a highly specialized and functionally distinct subset of natural killer cells expressing the memory-like activating receptor NKG2C and the maturation marker CD57. Adaptive memory NK cells have been clinically shown to have potent and persistent effector function in patients with AML.
Unlike T cells that require specific tumor antigen recognition to elicit an effective immune response, natural killer cells selectively identify and destroy cancer cells through recognition of a repertoire of stress signals commonly expressed across tumor cell types, while leaving normal healthy cells unharmed. Additionally, while T-cell immunotherapy most commonly requires a patient-specific treatment approach, natural killer cells sourced from healthy donors have been safely administered to patients for over a decade without causing graft-versus-host disease or triggering significant side effects, such as cytokine release syndrome.
The first-in-human study will evaluate the safety and determine the maximum dose of a single intravenous infusion of FATE-NK100 in subjects with refractory or relapsed AML. Secondary and investigational endpoints will assess anti-tumor activity including rates of complete response, clearance of minimal residual disease, disease-free survival and overall survival. The clinical trial will utilize an accelerated dose escalation design, which is intended to test up to four dose levels of FATE-NK100 with one subject enrolled per dose level until a dose-limiting toxicity (DLT) is observed. The study will convert to a 3+3 design in the event a DLT is observed, and will enroll a ten subject expansion cohort at the maximum dose level.
FATE-NK100 has demonstrated in preclinical studies enhanced anti-tumor activity across a broad range of liquid and solid tumors, improved persistence and increased resistance to immune checkpoint pathways compared to NK cell therapies that are being clinically administered. Additionally, FATE-NK100 has been shown in preclinical models to significantly augment antibody-directed cellular cytotoxicity against cancer cells when administered in combination with a monoclonal antibody, including antibodies that target CD20, HER2 and EGFR antigens. FATE-NK100 is produced through a feeder-free, seven-day manufacturing process during which natural killer cells sourced from a healthy donor are activated ex vivo with pharmacologic modulators, inducing the robust formation of adaptive memory NK cells.